Service Corporation International: Feeling Minimal Pressures


  • The themes are that COVID-19 pulled forward mortality, making 2020 and 2021 strong years for Service Corporation International.
  • There is also commentary around reduced discretionary spending, which is affecting the very cash and margin generative pre-need business and merchandise and services.
  • Nonetheless, the pressures are quite small and baby boomers are still entering the high mortality ages.
  • Also, US fertility is way better than many other western economies including Europe, so it's the right geography to get exposure.
  • The multiple is low and the outlook is very solid for decades, making SCI a buy.
  • Looking for a helping hand in the market? Members of The Value Lab get exclusive ideas and guidance to navigate any climate. Learn More »


D-Keine/E+ via Getty Images

Published on the Value Lab 5/9/22

We continue to build coverage in the death care sector with Service Corporation International (NYSE:SCI), probably the largest player in the US. It benefits relative to other geographies from solid US demographics, and the negative effects expected from strong comps were better than expected. The business is cash generative, and with both a strong medium-term and secular-term outlook, as well as a resilient short-term outlook, it looks like a solid value play.

Quick Primer

First, a quick primer on the business. They sell interment rights, so essentially leases, on their cemetery properties to customers on both an at-need and a pre-need basis, meaning either after someone's death or in anticipation of eventual death. In their cemetery merchandise and services, they floral services for the graves and other graveside services. They also provide funeral services, including cremation in addition to the cemetery arrangements, but also selling caskets or urns. The segment reporting is shown below.

sci segments

10-K 2021 Segments (

Here are some useful points about the economics of the business. When they sell on a pre-need basis, they create pre-need deferred revenue. This accounts for both cemetery and funeral segments. Naturally, once the services are rendered, revenue is recognised and the deferred revenue liability is nixed. In the meantime, it is a great source of cash flow, but cannot be used for working capital purposes. Much if not all of these pre-need sales are kept in trust funds, seen in the liabilities as deferred receipts held in trust, as per provincial or state law. The rest are deferred revenue, which reduces working capital as normal. If pre-need contracts are cancelled, the amounts retained by the company get recognized as revenue, including gains made on that portion of the funds in trust. This can all be considered a type of backlog, provided by pre-need sales activity.

sci balance sheet

10-Q2 Balance Sheet (

For the cemetery segment, it is basically a real estate business. They own 90% of their cemetery property and lease the rest. They in turn sell interment rights to customers for the place of memorial to remain. These are lump-sum sales that partially go into a perpetual care trust for upkeep of the cemetery according to local law, which is a liability. The part that goes into the trust is not recognized as revenue while the rest is. The trust is also invested in order to outpace the liability of the needs of the interments and to generate a profit. The investment returns from the trusts are recognized as cemetery segment revenue when distributed and help cover cemetery maintenance expenses. So essentially, the business model covers them for maintenance costs. Part of the COGS from cemeteries are property construction costs, in addition to all the other typical COGS-related costs that most other businesses would have, including labor and facility expenses.

The company also sometimes acts as an agent for selling life insurance policies on top of the sale of a pre-need contract. They earn commissions from insurance companies for this, and it comes in as general agency commissions.

Q2 Results

The Q2 Results are demonstrated as above and as follows.

sci results

Segment Results (

Funeral revenue rises, driven by the cash-generative pre-need segment. A good performance.

The cemetery revenue actually falls. Merchandise and services fall, having an amplified effect on the gross profits as it is a higher margin segment. Pre-need revenues fall slightly, showing a resilience in volumes just not mix.

Volumes, in general, are falling a little, while the average sale price is increasing. This is a key effect that is coming from the mortality pull-forward due to COVID-19, which really strengthened 2021 in particular, especially since funerals were slowed down by lockdowns. The reason the average sale is increasing is because more people are attending a given funeral. So larger rooms are being booked and larger services with more catering. Amusingly, funeral businesses are actually a reopening trade. On top of that, the company is beginning to pass along higher costs to consumers. As far as we're concerned, they will be able to stay ahead of inflation easily with pricing. On the flip side, cremations are growing, and that tends to be less favourable for the mix.

In general, management thinks that the flattish results are below their expectations and that the volumes being primarily affected are those related to discretionary spending. Funerals overall are not exactly discretionary, but some of the high contributors like merchandise are. To some extent, consumers are beginning to save on their funerals. Large sales are still growing, but it's in the more discounted services that we are seeing a bit of downtrading.

Another important comment is that the investment trusts have lost quite a bit of value due to the market crash this year. This is going to affect the revenue IV we get from the trusts, which need to grow to distribute nicely revenues above maintenance expenses coming from the part of cemetery sales that got put aside into trusts. Equity market conditions being rough and future returns likely to be muted is not a great thing for the company's secular revenue.


The company trades at 11.5x EV/EBITDA. That's pretty cheap for a business with this sort of hold on business cash flows. Moreover, the secular outlook is recession resistant and even good from a demographic perspective. The US has one of the best demographic profiles in the western world. The whole of the US is a fine proxy for SCI due to their national footprint and 16% market share.

US demographics

Population Pyramid US (

Dependency ratios are good, for the economy mainly, and there is a pretty even column for people to graduate by age into the SCI markets, i.e., after 75 where mortality starts to rise a whole lot. It's like a syringe of people into the higher mortality brackets, and it is loaded for the next 20 years. On that basis, this stock is a buy. The company has a low multiple and a very stable profile, with a great operating model to boot.

If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab. We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4%. We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some inspiration. Give our no-strings-attached free trial a try to see if it's for you.

This article was written by

Author of The Value Lab
A long-only voice with eclipsing growth through 2020 and 2022 bear markets.

Valkyrie Trading Society seeks to provide a consistent and honest voice through this blog and our Marketplace Service, the Value Lab, with a focus on high conviction and obscure developed market ideas.

DISCLOSURE: All of our articles and communications, including on the Value Lab, are only opinions and should not be treated as investment advice. We are not investment advisors. Consult an investment professional and take care to do your own due diligence.

DISCLOSURE: Some of Valkyrie's former and/or current members also have contributed individually or through shared accounts on Seeking Alpha. Currently: Guney Kaya contributes on his own now, and members have contributed on Mare Evidence Lab.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.